Receptor News and Research

RSS

Scientists uncover an important link between inflammation and breast cancer stem cells

Scientists at the University of Michigan Comprehensive Cancer Center have uncovered an important link between inflammation and breast cancer stem cells that suggests a new way to target cells that are resistant to current treatments.

4 Jan 2010

BioInvent International begins BI-505 drug study on patients with advanced multiple myeloma

BioInvent International AB announced today that the first patient has been treated in an open, dose-escalation phase I study of the company’s antibody BI-505 for patients with advanced multiple myeloma.

4 Jan 2010

Multivariable analyses identify epidemiological risk factors for ovarian cancer

Concentrations of the biomarkers CA125, human epididymis protein 4 (HE4), and mesothelin began to rise 3 years before clinical diagnosis of ovarian cancer, according to a new study published online December 30 in the Journal of the National Cancer Institute. However, the biomarkers became substantially elevated only in the last year prior to diagnosis.

31 Dec 2009

TRAP-1 may prevent cancer cell death, current research suggests

Current research suggests that TNF-receptor associated protein-1 (TRAP-1) may prevent cancer cell death. The related report by Leav et al, "Cytoprotective Mitochondrial Chaperone TRAP-1 as a Novel Molecular Target in Localized and Metastatic Prostate Cancer," appears in the January 2010 issue of the American Journal of Pathology.

30 Dec 2009

Results from Bionovo's study on BN107 published

Bionovo, Inc. announced today the publication of results from its study on the anti-tumor mechanism of BN107. The results of the study, published in the International Journal of Cancer, describe the potential molecular mechanisms mediating the selective pro-apoptotic (cell death) effect induced by BN107 on estrogen receptor negative (ER-) breast cancer cells.

29 Dec 2009

Study explains how semaphorin gene regulates synapse formation

By combining a research technique that dates back 136 years with modern molecular genetics, a Johns Hopkins neuroscientist has been able to see how a mammal's brain shrewdly revisits and reuses the same molecular cues to control the complex design of its circuits.

29 Dec 2009

American Diabetes Association recommends A1C test for diagnosing diabetes and identifying pre-diabetes

The American Diabetes Association's new Clinical Practice Recommendations being published as a supplement to the January issue of Diabetes Care call for the addition of the A1C test as a means of diagnosing diabetes and identifying pre-diabetes. The test has been recommended for years as a measure of how well people are doing to keep their blood glucose levels under control.

29 Dec 2009

E2F1 transcription factor inhibition reduces EGFR expression and invasive potential of melanoma cells

Inhibition of transcription factor E2F1 reduced epidermal growth factor receptor (EGFR) expression and reduced the invasive potential but not proliferation of metastatic melanoma cells, according to a brief communication published online December 23 in the Journal of the National Cancer Institute.

24 Dec 2009

New compound may halt drug-resistant lung cancer

The ability to make, test, and map the atomic structure of new anti-cancer agents has enabled a team of Dana-Farber Cancer Institute scientists to discover a compound capable of halting a common type of drug-resistant lung cancer.

24 Dec 2009

New energy receptor theory of brain function

Dr. Mitchell Earl Gibson, best-selling author, board-certified physician, and CEO of Tybro Publications, has proposed a new energy receptor theory of brain function that might explain the efficacy of mantras and prayer in human illness.

24 Dec 2009

Merck discontinues MK-1903 niacin receptor agonist development program with Arena Pharmaceuticals

Arena Pharmaceuticals, Inc. announced today Merck and Co., Inc.'s decision (through an affiliate) to discontinue development of MK-1903, an investigational niacin receptor agonist to treat atherosclerosis being developed under its research collaboration with Arena. Merck also informed Arena that the company will not continue the collaboration.

24 Dec 2009

Ligand Pharmaceuticals acquires Neurogen

Ligand Pharmaceuticals Incorporated announced today that it has completed the acquisition of Neurogen Corporation, following approval of the transaction by Neurogen stockholders earlier today. As a result, Ligand gains a fully funded partnership with Merck & Co., additional pipeline assets, drug discovery resources and additional cash balances.

23 Dec 2009

Achievements in lupus research, education and advocacy cause for celebration and hope

The year 2009 will be remembered as a year of many firsts for lupus, including the first successful phase III clinical trial of a potential new treatment for lupus, the launch of the first-ever Ad Council public awareness campaign for lupus, and the first comprehensive report on the barriers to lupus drug development. And it appears there are no signs of any slowing of momentum as we enter the New Year.

23 Dec 2009

Novel discovery offers hope for patients with common brain tumor

Biomedical researchers at the University of Central Florida have found a protein that could hold the key to treating one of the most common and aggressive brain tumors in adults.

23 Dec 2009

Johns Hopkins scientists find a source of nonallergic itch

Scratching below the surface of a troublesome sensation that's equal parts tingle-tickle-prickle, sensory scientists from Johns Hopkins have discovered in mice a molecular basis for nonallergic itch.

23 Dec 2009

Hormone ghrelin influences the consumption of alcohol, study shows

A Faculty of 1000 evaluation examines how a stomach-produced hormone that influences the desire to eat and consume alcohol could be switched off to control drinking problems.

23 Dec 2009

New project analyzes genetic sequence and variations of every gene expressed by 1,000 tumors

No two tumors are alike, but analyzing the genetics of cancers from different parts of the body may reveal surprising details useful for treatment and prevention.

22 Dec 2009

Endocannabinoid modulation of sweet taste receptors may help control feeding behavior

Sweet taste responses were enhanced by endocannabinoids in every case. The effect was specific for sweet taste, as endocannibinoids had no effect on responses to sour, salty, bitter or umami taste stimuli.

22 Dec 2009

3rd Annual OneMedForum to highlight therapeutic and diagnostic products for cancers

ProActive Capital Resources Group, a company dedicated to the discovery and creation of value in the small and micro-cap marketplace, is proud to announce client presentations at the 3rd Annual OneMedForum held in San Francisco, January 12-13, 2010. ProActive clients presenting are: Access Pharmaceuticals, ImmunoCellular Therapeutics, DataTrak International, Quantum Immunologics, with Protox Therapeutic's presentation pending.

22 Dec 2009

Clarient announces acquisition of Applied Genomics

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that it has acquired privately held, Huntsville, AL-based Applied Genomics, Inc. (AGI) in an all-stock merger valued at up to $17.6 million, if all conditions and milestones set forth in the merger agreement are successfully met.

21 Dec 2009

Receptor News and Research

Scientists uncover an important link between inflammation and breast cancer stem cells

BioInvent International begins BI-505 drug study on patients with advanced multiple myeloma

Multivariable analyses identify epidemiological risk factors for ovarian cancer

TRAP-1 may prevent cancer cell death, current research suggests

Results from Bionovo's study on BN107 published

Study explains how semaphorin gene regulates synapse formation

American Diabetes Association recommends A1C test for diagnosing diabetes and identifying pre-diabetes

E2F1 transcription factor inhibition reduces EGFR expression and invasive potential of melanoma cells

New compound may halt drug-resistant lung cancer

New energy receptor theory of brain function

Merck discontinues MK-1903 niacin receptor agonist development program with Arena Pharmaceuticals

Ligand Pharmaceuticals acquires Neurogen

Achievements in lupus research, education and advocacy cause for celebration and hope

Novel discovery offers hope for patients with common brain tumor

Johns Hopkins scientists find a source of nonallergic itch

Hormone ghrelin influences the consumption of alcohol, study shows

New project analyzes genetic sequence and variations of every gene expressed by 1,000 tumors

Endocannabinoid modulation of sweet taste receptors may help control feeding behavior

3rd Annual OneMedForum to highlight therapeutic and diagnostic products for cancers

Clarient announces acquisition of Applied Genomics

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News